The aim of the present study was to investigate whether CYP2C19 polymorphism status and gastric emptying are related to healing in patients with gastric ulcers. We studied the CYP2C19 status in seven patients with proton pump inhibitor (PPI)-resistant ulcers, 21 with PPI-sensitive ulcers and 46 healthy volunteers using polymerase chain reaction restriction fragment length polymorphism to detect CYP2C19m1 mutation in exon 5 and CYP2C19m2 mutation in exon 4. Gastric emptying was evaluated using the 13 C-acetate breath test. The frequency of phenotypes, indicated by genotypes, did not differ significantly between the three patient groups. The peak time of 13 C excretion in patients with PPIresistant ulcers was significantly longer than that of patients with PPI-sensitive ulcers and healthy volunteers. Our results suggest that rate of gastric emptying, but not CYP2C19 polymorphism, is likely to be an important factor in the delayed healing of patients with PPI-resistant gastric ulcer.
Introduction
Proton pump inhibitors (PPIs) are fairly new anti-ulcer agents that inhibit the function of the proton pump (H + , K + -ATPase) responsible for the terminal step in gastric-acid secretion. They have a more sustained acid secretion inhibitory action and higher rate of peptic ulcer disease healing than histamine type 2 receptor antagonists. 1, 2 It is clear, however, that 5 -10% of gastric ulcers do not heal within a given period (6 -8 weeks) of treatment, even with PPIs. Such peptic ulcers have been termed PPI resistant, intractable or refractory. 3 -5 The pathological mechanism of PPI resistance is unknown, but several aetiological factors have been suggested, such as insufficient suppression of gastric-acid secretion, 6, 7 reduced gastric emptying, 8, 9 and non-steroidal anti-inflammatory drug (NSAID) administration. 10, 11 Recent studies have reported that an isozyme of cytochrome P450 (CYP) in the liver, CYP2C19, plays an important role in the catabolism of PPI. There are two genetically determined phenotypes, extensive CYP2C19 metabolizer and poor CYP2C19 metabolizer. Phenotype variation influences gastric-acid suppression, such that poor metabolizers have a higher plasma concentration of PPI and a higher intragastric pH than extensive metabolizers. 12 -14 Proton pump inhibitors are not resistant to acid, and are therefore manufactured as acid-resistant, enteric-coated preparations. When PPIs remain in the stomach for a prolonged period, however, they may be inactivated by gastric acid. 15, 16 It is therefore important to evaluate gastric emptying in patients with PPI-resistant ulcers. We employed the 13 C-acetate breath test, which is a recently developed procedure that uses a non-radioactive isotope with high sensitivity and specificity. 17, 18 The aim of the present study was to determine whether CYP2C19 polymorphism status and gastric emptying are related to the healing of gastric ulcers.
Patients and methods

PATIENTS
We studied seven patients with a diagnosis of PPI-resistant gastric ulcer (four men and three women), 21 PPI-sensitive gastric ulcer patients (18 men and three women), confirmed by endoscopy, and a control group of 46 healthy volunteers or patients endoscopically confirmed to be free of gastric ulcers (29 men and 17 women) at five hospitals (Nagasaki Municipal Hospital, Nagasaki Municipal Medical Centre, Kubo Hospital, Senju Hospital and Nagasaki University Hospital) in the Nagasaki prefecture from January 1999 to January 2002. In this study, PPI-resistant gastric ulcers were defined as gastric ulcers that failed to heal following an 8-week course of PPIs, while PPI-sensitive ulcers were those that healed within the same treatment period. Informed consent was obtained from all patients, and the study protocol was approved by the ethics committee of Nagasaki University.
LIFESTYLE AND HELICOBACTER PYLORI STATUS
Smoking habits and NSAID use were recorded using questionnaires. The presence of Helicobacter pylori, which is closely associated with gastritis and peptic ulcer disease, was confirmed by serology (anti-H. pylori immunoglobulin antibody, HEL-p TEST, Amrad Co., Melbourne, Australia), the rapid urease test (CLO test, Delta West Co., Bentley, Australia) and histology (Giemsa staining) using biopsy specimens obtained during endoscopy from the antrum and corpus along greater curvature.
DETECTION OF CYP2C19 POLYMORPHISM
Blood samples were collected to determine the CYP2C19 genotype. Genomic DNA was isolated from peripheral whole blood using a DNA Extractor WB Kit (Wako Pure Chemical Industries, Tokyo, Japan). The polymorphism of CYP2C19 was identified by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP).
CYP2C19m1 polymorphism in exon 5
To detect the polymorphism of CYP2C19m1 in exon 5, we used the forward primer (5'-AAT TAC AAC CAG AGC TTG GC-3') and reverse primer (5'-TAT CAC TTT CCA TAA AAG CAA G-3'). The PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 ) contained 250 µM deoxyribonucleoside triphosphate (dNTP), 0.5 µM of each primer and 2.5 units of AmpliTaq DNA polymerase (Takara Shuzo Co., Shiga, Japan). Amplification was performed in a Perkin-Elmer thermocycler under the following conditions: an initial denaturation step at 94°C for 3.5 min, then 35 cycles consisting of denaturation at 94°C for 1 min, annealing at 52°C for 1.5 min, and extension at 72°C for 1.5 min, followed by a final extension at 72°C for 4.5 min. 19
CYP2C19m2 polymorphism in exon 4
For detection of polymorphism of CYP2C19m2 in exon 4, we used the forward primer (5'-TAT TAT TAT CTG TTA ACT AAT ATG A-3'), and the reverse primer (5'-ACT TCA GGC CTT GGT CAA TA-3'). The PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 3.0 mM MgCl 2 ) contained 200 µM dNTP, 0.25 µM of each primer and 6.25 units of AmpliTaq DNA polymerase (Takara Shuzo Co., Kyoto, Japan). Amplification was performed in a Perkin-Elmer thermocycler set with an initial denaturation step at 94°C for 3.5 min, then 35 cycles consisting of denaturation at 94°C for 1 min, annealing at 53°C for 0.5 min, and extension at 72°C for 0.5 min, followed by a final extension at 72°C for 4.5 min. 19 Polymerase chain reaction products were digested overnight with the restriction enzymes SmaI and BamHI (Takara Shuzo Co., Kyoto, Japan) at 25°C. Both digests underwent electrophoresis in 3% NuSieve 3:1 agarose (FMC Bio Products, Philadelphia, PA, USA), and were visualized with ethidium bromide in an Alpha Imager (Alpha Innotech Co., San Leandro, CA, USA).
We elucidated three genotypes for poor metabolizers (m1/m1, m2/m2 or m1/m2), although De Morais et al. 20 report that, for extensive metabolizers, there are two genotypes, homozygous (wt/wt) and heterozygous (wt/m1 or wt/m2).
13
C-ACETATE BREATH TEST
We used the 13 C-acetate breath test, described previously by Ghoos et al. 21 and Urita et al., 22 to analyse gastric emptying. The test was performed simultaneously in five PPI-resistant ulcer patients, five PPI-sensitive ulcer patients and five healthy volunteers. Any medications that affect gastrointestinal motility were discontinued 3 days prior to the study. All gastric-emptying tests were performed at 09.00 following an overnight fast. The liquid test meal (OKUNOS-A, 200 ml/200 kcal; Forica Foods Co., Niigata, Japan) and 100 mg of 13 C-acetate (CIL Japan, Osaka, Japan) were administered orally. Breath samples for 13 CO 2 measurements were collected in air bags at baseline (before the test meal), and every 10 min up to 120 min after intake of the test meal. 13 C enrichment was measured using a UBit-IR200 spectrophotometer (Otsuka Pharmaceuticals, Tokyo, Japan). Data are expressed as time of peak 13 C exhalation.
STATISTICAL ANALYSIS
Differences in the proportion of poor metabolizers among patients with PPIresistant gastric ulcers, patients with PPIsensitive ulcers, and control volunteers were analysed for statistical significance using the χ 2 test. The time to peak 13 CO 2 excretion was analysed using the Dunnet and Tukey test following analysis of variance. P-values < 0.05 were considered to be statistically significant.
Results
CLINICAL FEATURES OF PPI-RESISTANT PATIENTS
The age range did not differ significantly between the three groups ( Table 1) . Four patients were positive for H. pylori, four were smokers and only one was being treated with NSAIDs ( Table 2) . Of the seven patients with PPI-resistant ulcers, two were treated with omeprazole, one with lansoprazole and four with rabeprazole (Table 3 ).
POLYMORPHISM OF CYP2C19
Of the seven patients with PPI-resistant ulcers, two (28.6%) were homozygous (Table 4 ). Of the two heterozygous extensive metabolizers, one was heterozygous for the CYP2C19m1 mutation (wt/m1), and the other was heterozygous for the CYP2C19m2 mutation (wt/m2) ( Table 3 ). Of the three poor metabolizers, one was heterozygous (m1/m2) with the two defects in exon 5 and 4, and two were homozygous (m1/m1) with the defect in exon 5 (Fig. 1) . In 21 PPIsensitive gastric ulcer patients, five (23.8%) were homozygous, 14 (66.7%) were heterozygous extensive and two (9.5%) were poor metabolizers (Table 4 ). In the control group, 19 (41.3%) were homozygous extensive metabolizers, 21 (45.7%) were heterozygous, and six (13.0%) were poor metabolizers ( Table 4 ). The frequency of poor metabolizers in PPI-resistant ulcer patients tended to be higher than that in PPI-sensitive ulcer patients and healthy individuals. The difference in frequency of phenotypes in each group, however, was not statistically significant.
GASTRIC EMPTYING
The mean time to peak 13 CO 2 excretion in patients with PPI-resistant ulcers, PPIsensitive ulcers and control individuals were 82.0 ± 24.9 min, 50.0 ± 7.1 min and 58.0 ± 4.5 min, respectively (Fig. 2 ). The mean time to peak 13 CO 2 excretion of patients with PPIresistant ulcers was significantly longer than that of PPI-sensitive ulcer patients (P < 0.05) and control volunteers (P < 0.05) (Fig. 2) . There was no significant difference between PPI-sensitive ulcer patients and control volunteers. 
Discussion
The accurate underlying mechanism of PPI resistance in some peptic ulcer patients has not yet been identified, although several factors such as impaired acid suppression and gastric mobility have been proposed. 6 -9 Smoking and NSAID use are also considered to be important factors in patients with this type of ulcer. 10, 11 Only three of the seven patients in this study were non-smokers and only one was being treated with NSAIDs, however, so it is unlikely that these two factors cause PPI resistance.
Three PPIs available in Japan, omeprazole, lansoprazole and rabeprazole, undergo extensive hepatic biotransformation. In the liver, they are metabolized to differing degrees by several CYP isozymes, the principal isozyme in PPI metabolism being CYP2C19. These isozymes are categorized into subfamilies of related polymorphic gene products. 12, 13 The CYP2C19 gene is located on chromosome 10p, and at least two mutations, CYP2C19m1
and CYP2C19m2, are known to be associated with genetic deficiency of this metabolic activity. 20, 21 CYP2C19 has two genetically determined phenotypes, extensive metabolizer and poor metabolizer. Using PCR-RFLP, both mutant alleles have been shown to explain 100% of Japanese poor metabolizers available. 22, 23 Chang et al. 24 reported that, in poor metabolizers, the area under the concentration curve of omeprazole was 20 times greater than that of homozygous extensive metabolizers. Furuta et al. 25 studied the effects of omeprazole on 24-h intragastric pH in relation to the three different CYP2C19 genotypes, and reported that mean intragastric pH values in homozygous extensive metabolizers, heterozygous extensive metabolizers and poor metabolizers were 2.14, 3.30 and 4.47, respectively. Thus, acid secretion in an individual receiving omeprazole therapy who is a poor metabolizer of CYP2C19 is thought to be more strongly suppressed than in those who are extensive metabolizers. Our hypothesis was, therefore, that the frequency of poor metabolizers in patients with PPI-resistant ulcers would be lower than that in patients who are PPI sensitive or in healthy controls. Although the pharmacokinetics were not examined, we speculate that our genotype results are probably compatible with those of previous studies in healthy populations. Our results showed no significant differences in the frequency of poor metabolizers between the three groups.
The incidence of poor metabolizers has been shown to have a marked inter-ethnic difference: 2 -6% in the white population; 20, 26 13 -23% in the oriental population; 25, 27 and 19 -23% in Japan. 22, 28 In our study, 14.9% of the entire study population were poor metabolizers, which is almost the same as in previously published studies.
Proton pump inhibitors are slightly alkaline and not resistant to acid. When a sample of PPI was placed in pH 1.2 aqueous solution, the half-life was extremely shortabout 2 min. 15 Previous studies in humans confirmed that PPIs are broken down in the stomach after administration. 16 They are therefore dispensed as acid-resistant, entericcoated preparations. When PPIs remain in the stomach for a prolonged period because of slow gastric emptying, however, they may be inactivated by gastric acid. Based on this hypothesis, the effects of gastric emptying on ulcer healing were investigated.
Radioscintigraphy is generally considered to be the gold standard for evaluating gastric emptying, 17, 29 and it is frequently used for the diagnosis of gastroparesis in conditions such as acid-reflux disease, diabetes mellitus, AIDS and amyotrophic lateral sclerosis. 30 -32 Disadvantages of this method include its high cost and the use of radiochemicals, in addition to the risks associated with radiation exposure. In Japan, the acetaminophen method is widely used to evaluate the gastric emptying rates for liquids. This method is associated with the risk of severe hepatotoxicity when high doses are used. 33, 34 The 13 C-acetate breath test was recently developed as an easy-to-perform non-radioactive alternative for the analysis of gastric-emptying rates with high sensitivity and specificity. 17, 18 In assessing gastric emptying using this method, Ghoos et al. 21 analysed three parameters, the gastricemptying coefficient, the gastric halfemptying time and the lag phase. These parameters are complex and difficult to calculate, so we used the simpler parameter, time to peak 13 CO 2 excretion.
Kanaizumi et al. 35 reported that gastric emptying in patients with gastric ulcers was rapid, while others reported that the mean gastric-emptying time in patients with peptic ulcers and healthy individuals was similar. 36, 37 Using the acetaminophen test, Ashida et al. 9 concluded that PPI-resistant ulcers appear to result from insufficient inhibition of gastric acidity, and that slow gastric emptying interferes with the absorption of PPIs. Our data showed that the time to peak 13 CO 2 excretion in patients with PPI-resistant ulcers was longer than patients with PPI-sensitive ulcers and healthy volunteers, but there was no significant difference between patients with PPIsensitive ulcers and the control group. Thus, the effect of orally administered PPIs may be reduced in patients with delayed gastric emptying. Changing the PPI formulation and increasing the dose to compensate for slow gastric emptying may be effective approaches when treating patients with PPI-resistant gastric ulcers.
In conclusion, we have demonstrated that time to peak 13 CO 2 excretion, measured by the 13 C-acetate breath test, was longer in patients with PPI-resistant ulcers than in those with PPI-sensitive ulcers and control F Wada, K Murase, H Isomoto et al. CYP2C19 polymorphisms and gastric emptying individuals. Our results also showed that CYP2C19 polymorphisms are not associated with differing responses to PPI therapy.
Gastric emptying seems to be an important factor in the delayed healing of gastric ulcers.
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